Grace Therapeutics, Inc. (GRCE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.26 |
| Open | 2.29 |
| Day High | 2.46 |
| Day Low | 2.2 |
| 52-Week High | 5.18 |
| 52-Week Low | 1.79 |
| Volume | 715,952 |
| Average Volume | 225,772 |
| Market Cap | 36.13M |
| PE | -1.85 |
| EPS | -1.2 |
| Moving Average 50 Days | 2.24 |
| Moving Average 200 Days | 3.06 |
| Change | -0.04 |
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being d
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
GlobeNewswire Inc.
Nov 11, 2025 1:30 PM GMT
STRIVE-ON Results Accepted for Late-Breaking PresentationPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-s